drugset / Trial / NCT05211232

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

NCT05211232

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy combined with tislelizumab in adjuvant therapy of locoregionally advanced nasopharyngeal carcinoma patients.

Timeline

Start
2022-06-10
Primary completion
2026-06-02
Completion
2028-06-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous